TWD
RXRX icon

True Wealth Design’s Recursion Pharmaceuticals RXRX Stock Holding History

True Wealth Design’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-194
Closed -$712 – 2749
2026
Q2 		$712 Buy
194
+186
+2,325% +$619 ﹤0.01% 2095
2026
Q1 		$25 Buy
+8
New +$31 ﹤0.01% 2628
2025
Q2 		– Sell
-485
Closed -$2.57K – 2799
2025
Q1 		$2.57K Buy
+485
New +$3.54K ﹤0.01% 923

Other funds holding RXRX

GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
CCIA
Cherry Creek Investment Advisors Englewood, Colorado $261M AUM 29.65% 1-Year Est. Return
WWM
Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return
KG
Kieckhefer Group Mequon, Wisconsin $252M AUM 40.97% 1-Year Est. Return
AWM
Accel Wealth Management Waverly, Iowa $464M AUM 21.88% 1-Year Est. Return
Wedmont Private Capital
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
TWM
TriaGen Wealth Management Calabasas, California $413M AUM 35.91% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

True Wealth Design's RXRX Position: Q3 2026 in Review

True Wealth Design sold out of Recursion Pharmaceuticals (RXRX) in Q3 2026, closing a stake of 194 shares — an estimated $712 sold.

True Wealth Design first reported a position in RXRX in Q1 2025 and held it in 3 quarters. The position peaked at $2.57K in Q1 2025. 20 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • True Wealth Design reported no remaining Recursion Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • True Wealth Design sold 194 Recursion Pharmaceuticals shares in Q3 2026, an estimated $712.
  • True Wealth Design first reported a position in Recursion Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • True Wealth Design's Recursion Pharmaceuticals position peaked at $2.57K in Q1 2025.
  • 20 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.